Loading...
Please wait, while we are loading the content...
Similar Documents
Biological therapy of psoriasis
| Content Provider | Scilit |
|---|---|
| Author | Maverakis, Emanual Bowen, MichaelP Raychaudhuri, SibaP Sivamani, RajaK Correa, Genevieve Ono, Yoko |
| Copyright Year | 2010 |
| Abstract | The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF-α agents have been associated with a variety of serious and “routine” opportunistic infections. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887522/pdf |
| Ending Page | 170 |
| Page Count | 10 |
| Starting Page | 161 |
| File Format | XHTML |
| ISSN | 00195154 |
| e-ISSN | 19983611 |
| DOI | 10.4103/0019-5154.62754 |
| Journal | Indian Journal of Dermatology |
| Issue Number | 2 |
| Volume Number | 55 |
| Language | English |
| Publisher | Medknow |
| Access Restriction | Open |
| Subject Keyword | Adverse Effects Biologics Psoriasis Therapy Indian Journal of Dermatology, Volume 55, Issue 2 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Dermatology |
